Gordian Biotechnology

After years of hype, AI-designed drugs are falling short in the clinic. Why? For AI to succeed in drug discovery, training data must come from living mammals. While efficacy and safety must be validated in a living organism (in vivo), cost and efficiency has forced drug discovery to seek out simplified systems to run tests at scale. This means drug discovery models are being trained in the wrong system. You don’t train a self-driving car on the California Vehicle Code, you train it on the road. If you’re going to test your drug in a living mammal, you must train for discovery in that living mammal. Read the full post here: https://lnkd.in/e9uKdvUq

Whatever your fears about the election, Gordian Biotechnology is hiring people to make fear of disease a thing of the past. We don’t settle for “good enough”—high-throughput in vivo screening allows for preclinical testing of vastly more targets, raising the bar for progressing to clinical trials and ensuring only the most effective therapeutics advance. If you’re passionate about innovative science and want to be part of a team that's redefining drug discovery, check out our open positions! ?? Scientist, Complex Ex Vivo Systems (Osteoarthritis) ?? If working on cutting-edge models for osteoarthritis and leading ex vivo experiments sounds like your calling, we want to hear from you! You’ll spearhead ex vivo validation experiments for our OA program, designing assays to evaluate therapeutic candidates using human chondrocytes and knee joint explants. ?? Senior Scientist, Complex Ex Vivo Systems & Assay Development ?? Love working with advanced tissue cultures? We’re looking for someone to lead the design and optimization of ex vivo experiments for validating therapeutic targets in pulmonary fibrosis, heart failure, and MASH programs, establishing human tissue models, and developing assays for safety and efficacy—all while driving forward innovation in the quest to cure age-related diseases. ?? RA2/SRA In Vivo Heart Failure ?? You’ll execute high-impact experiments, including in vivo assays, performing echocardiography, conducting exercise testing, and analyzing tissue samples. Your contributions will directly impact our understanding of heart failure and help drive the development of new drug candidates. Sound interesting? Please apply! Let’s push the boundaries of what’s possible in drug discovery together. https://lnkd.in/gwFgvT3T

We loved listening to Martin Borch Jensen and Patrick Short on this fantastic episode! Thanks to Patrick and Sano Genetics for investing their time and other resources on the show to bring the most compelling topics in biotech to light. We appreciate you! #InVivoVeritas #GeneTherapy #Longevity

Summer intern Isabel Matteo just posted about her experience at Gordian, researching philosophies and best practices for biotech and pharma R&D, and learning to love cold emailing. Enjoy! https://lnkd.in/eNcZzcKe

Thank you to Michael Eisenstein and Lisa Melton at Nature Portfolio for the excellent piece on how Gordian and others are leading a shift toward high-throughput in vivo screening models to generate physiologically relevant data and, in Gordian’s case, better predict what gene targets will most likely to succeed in human trials for age-related disease. Read the article here: https://lnkd.in/gBcX_BbD.? #InVivoVeritas #InVivoScreening #GeneTherapy

Join Women In Bio – SF Bay Area Chapter for an informal networking event with local professionals. The event is open to WIB members and nonmembers, women and allies, and anyone interested in learning more about the Bay Area’s biotech scene. Look for the Women in Bio logo upon arrival. ? RSVP by LinkedIn and invite your friends to join. ? Complimentary drinks and small bites will be available. ? Transit: Deep Origin is accessible by BART and SamTrains at South San Francisco Station. There are parking garages and street parking available.

Thank you so much to Jason Carman, Julia Bauman, Elliot Hershberg, and Wellington Bowler! It was great to host them and over 100 scientists and entrepreneurs at our HQ!

Interesting article from Francisco LePort, where Nenad Marovac DN Capital and I have a small investment...

A must-read piece on in-vivo screening written by the amazing founders of Gordian Biotechnology Francisco LePort Martin Borch Jensen

Disease happens in a systemic context... the best disease models should recapitulate as much of that context as possible!